ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Company profile
Ticker
RARE
Exchange
Website
CEO
Emil Kakkis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Ultragenyx Holdco LLC • Rare Delaware Inc. • GeneTx Biotherapeutics LLC • Ultragenyx UK Ltd • Amlogenyx Inc. • Ultragenyx Europe GmbH • Ultragenyx Germany GmbH • Ultragenyx Brasil Farmacêutica Ltda • Ultragenyx Argentina SRL • Ultragenyx Netherlands B.V. ...
IRS number
272546083
RARE stock data
Latest filings (excl ownership)
8-K
Other Events
15 Apr 24
S-3ASR
Automatic shelf registration
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
15 Feb 24
8-K
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
2 Nov 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
424B5
Prospectus supplement for primary offering
20 Oct 23
Transcripts
RARE
Earnings call transcript
2023 Q4
15 Feb 24
RARE
Earnings call transcript
2023 Q3
2 Nov 23
RARE
Earnings call transcript
2023 Q2
3 Aug 23
RARE
Earnings call transcript
2023 Q1
4 May 23
RARE
Earnings call transcript
2022 Q4
16 Feb 23
RARE
Earnings call transcript
2022 Q3
2 Nov 22
RARE
Earnings call transcript
2022 Q2
29 Jul 22
RARE
Earnings call transcript
2022 Q1
6 May 22
RARE
Earnings call transcript
2021 Q4
11 Feb 22
RARE
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Eric Crombez
19 Apr 24
4
Theodore Alan Huizenga
18 Apr 24
4
Thomas Richard Kassberg
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Matthew K Fust
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
Howard Horn
5 Mar 24
4
Karah Herdman Parschauer
5 Mar 24
4
Thomas Richard Kassberg
5 Mar 24
4
Dennis Karl Huang
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.61 mm | 78.61 mm | 78.61 mm | 78.61 mm | 78.61 mm | 78.61 mm |
Cash burn (monthly) | 9.69 mm | 26.48 mm | 53.00 mm | 52.90 mm | 39.29 mm | 40.10 mm |
Cash used (since last report) | 66.74 mm | 182.39 mm | 365.13 mm | 364.47 mm | 270.69 mm | 276.29 mm |
Cash remaining | 11.87 mm | -103.79 mm | -286.52 mm | -285.87 mm | -192.08 mm | -197.68 mm |
Runway (months of cash) | 1.2 | -3.9 | -5.4 | -5.4 | -4.9 | -4.9 |
Institutional ownership, Q2 2023
87.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 239 |
Opened positions | 43 |
Closed positions | 28 |
Increased positions | 88 |
Reduced positions | 78 |
13F shares | Current |
---|---|
Total value | 3.17 tn |
Total shares | 71.60 mm |
Total puts | 296.50 k |
Total calls | 257.00 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 7.02 mm | $323.76 bn |
RTW Investments | 5.41 mm | $249.34 bn |
Wellington Management | 5.18 mm | $238.84 bn |
BLK Blackrock | 5.07 mm | $233.74 bn |
T. Rowe Price | 3.61 mm | $168.82 bn |
CPNEX New Perspective Fund | 2.77 mm | $120.37 mm |
Clearbridge Advisors | 2.76 mm | $127.47 bn |
Sands Capital Management | 2.67 mm | $123.33 bn |
STT State Street | 2.47 mm | $113.73 bn |
Alkeon Capital Management | 1.94 mm | $89.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Eric Crombez | Common Stock | Sell | Dispose S | No | No | 44.1 | 142 | 6.26 k | 48,785 |
16 Apr 24 | Theodore Alan Huizenga | Common Stock | Payment of exercise | Dispose F | No | No | 42.31 | 14 | 592.34 | 41,366 |
11 Mar 24 | Thomas Richard Kassberg | Common Stock | Sell | Dispose S | No | No | 49.93 | 11,509 | 574.64 k | 252,823 |
7 Mar 24 | Fust Matthew K | Common Stock | Sell | Dispose S | No | No | 50.88 | 7,500 | 381.60 k | 14,860 |
7 Mar 24 | Fust Matthew K | Common Stock | Sell | Dispose S | No | No | 50.85 | 2,145 | 109.07 k | 22,360 |
7 Mar 24 | Fust Matthew K | Common Stock | Sell | Dispose S | No | No | 50.89 | 2,550 | 129.77 k | 24,505 |
1 Mar 24 | Horn Howard | Common Stock | Grant | Acquire A | No | No | 0 | 19,400 | 0.00 | 99,766 |
1 Mar 24 | Horn Howard | Stock Option Common Stock | Grant | Acquire A | No | No | 53.69 | 34,200 | 1.84 mm | 34,200 |
News
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61
24 Apr 24
RBC Capital Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $77
22 Apr 24
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
17 Apr 24
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
16 Apr 24
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
15 Apr 24
Press releases
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
25 Apr 24
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 Apr 24
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
15 Apr 24
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
12 Apr 24
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
12 Apr 24